Kala Bio (LTS:0JQ2) Short-Term Debt : $5.99 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Kala Bio Short-Term Debt?

Kala Bio's Short-Term Debt for the quarter that ended in Mar. 2024 was $5.99 Mil.

Kala Bio's quarterly Short-Term Debt stayed the same from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($5.99 Mil).

Kala Bio's annual Short-Term Debt increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($5.00 Mil) but then declined from Dec. 2022 ($5.00 Mil) to Dec. 2023 ($0.00 Mil).

Kala Bio Short-Term Debt Historical Data

The historical data trend for Kala Bio's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kala Bio Short-Term Debt Chart

Kala Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

5.00

Kala Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	5.99

Kala Bio Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Kala Bio Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Kala Bio's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Kala Bio (LTS:0JQ2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kala Bio Inc (LTS:0JQ2) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

KALA:USA 27F0:Germany

Address

1167 Massachusetts Avenue, Arlington, MA, USA, 02476

Website

https://www.kalarx.com

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe eye diseases. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Kala Bio (LTS:0JQ2) Headlines

No Headlines